Navigation Links
Results of Boehringer Ingelheim Oral Hepatitis C Protease Inhibitor and Polymerase Inhibitor Combination Phase Ib Trial Shows Rapid Viral Response Without Use of Pegylated Interferon
Date:10/30/2010

BOSTON and RIDGEFIELD, Conn., Oct. 30, 2010 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today results from a Phase Ib study, SOUND-C1, that showed the combination of two oral hepatitis C virus (HCV) compounds, the protease inhibitor BI 201335 and the polymerase inhibitor BI 207127, with ribavirin reduced viral load below the lower limit of quantifiable levels in HCV treatment-naive patients. The regimen did not include interferon through the first 28 days of treatment. These data are being presented at the American Association for the Study of Liver Diseases (AASLD) 2010 Liver Meeting in Boston, MA.

(Poster LB-7) New protease-polymerase inhibitor combination resulted in 73-100% rapid virological responses without pegylated interferonIn this randomized open-label trial, 32 treatment-naive genotype-1 HCV patients received BI 207127 in either 400mg or 600mg doses three times a day (TID), BI 201335 120mg once daily (QD) and ribavirin (RBV) (1000/1200mg daily in two doses) for 28 days. All patients had a rapid and sharp decline in HCV viral load during the first two days, followed by a slower second phase decline. In the lower and higher dose groups, 73 and 100% of patients achieved a rapid virological response (i.e. HCV RNA below lower limit of quantification after 4 weeks of treatment). One patient experienced a viral breakthrough (increase by >1 LOG10 from nadir during treatment) and one other experienced a 0.7 LOG10 increase in viral load. Both were in the lower dose group of BI 207127 and were patients with high baseline viral load. On day 29, all patients were switched to treatment with BI 201335 and PegIFN/RBV for an additional 44 weeks per the defined study protocol, and will be followed to evaluate sustained virological response.

"The current standard-of-care, PegIFN/RBV, is challenging for patients with chronic hepatitis C due to significant side effects that impact treatment adherence and has suboptimal response
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
5. Tapestry Reports Second Quarter 2007 Results
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 19, 2014 You,re visiting the ... and cleaning when he or she says you need ... heard before, you may have several questions and feel ... relieved to know it,s nothing to worry about. The ... questions and alleviate any anxiety the public may have ...
(Date:12/19/2014)... HILL, N.C. , Dec. 19, 2014 /PRNewswire/ ... to optimize a product,s web presence to reflect ... Brand websites, in particular, must meet the needs ... regulations and culture. According to ... more than half of the participating companies averaged ...
(Date:12/19/2014)... WORTH, Texas , December 18, 2014 /PRNewswire/ ... a networked software application/module that is used to ... related images. RIS comprises a patient tracking and ... system. The integration of RIS with HIS and ... used for patient registration and patient scheduling, patient ...
Breaking Medicine Technology:Root Canals Have Become More Routine 2Building a Best-in-Class Pharma Global Brand Website 2The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 2The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 3
... Pharmasset, Inc. (Nasdaq: VRUS ) announced today ... exercised their option to purchase from Pharmasset an additional ... Pharmasset after deducting the underwriting discount, from the sale ... $21.9 million. This brings the total expected net proceeds ...
... WASHINGTON, Jan. 24, 2011 More than 300 million Americans ... the flu annually. But for the 60 million people who ... pose even greater risks. Together, these respiratory diseases take a ... direct medical expenses, reducing quality of life, lowering workplace and ...
Cached Medicine Technology:Pharmasset Announces Exercise of Underwriters' Overallotment Option 2Pharmasset Announces Exercise of Underwriters' Overallotment Option 3Survey Finds Patients Oppose Prescription Mandate for OTC Medicines Containing Pseudoephedrine 2Survey Finds Patients Oppose Prescription Mandate for OTC Medicines Containing Pseudoephedrine 3Survey Finds Patients Oppose Prescription Mandate for OTC Medicines Containing Pseudoephedrine 4Survey Finds Patients Oppose Prescription Mandate for OTC Medicines Containing Pseudoephedrine 5
(Date:12/22/2014)... CA (PRWEB) December 22, 2014 The ... PALS, BLS and ACLS online certification provider, are proud ... http://www.acls-pals-bls.com . The updated site now features a more ... than ever to use. , As a company ... information is now consolidated into a single page during ...
(Date:12/22/2014)... Harrisburg, NC (PRWEB) December 22, 2014 ... contain the current Ebola virus epidemic are ... by U.S. government agencies, nongovernmental organizations (NGOs) ... solutions remains ongoing, healthcare workers, emergency responders, ... advanced technologies such as the CmTP ...
(Date:12/22/2014)... 22, 2014 Physicians in China are ... the treatment of non-Hodgkin’s lymphoma (NHL), according to a ... global healthcare consulting firm. MabThera is the only biologic ... most common form of NHL. , According to Kantar ... the incidence of NHL in China has been growing ...
(Date:12/22/2014)... Explorys, the leader in big data-driven ... team: Greg Yarrington as Vice President of Operations, Adam ... as Vice President of Solutions. These new leaders are ... in 2015 to support client demand for the company’s ... and growth of its partner network. , Since ...
(Date:12/22/2014)... 2014 In recognition of Veteran’s Day, ... Hero Reward, a local organization that provides services to ... , Located on a couple hundred acres in the ... lodging, world class fishing, hunting, hiking, horseback riding, 4-wheeling, ... several years ago to support U.S. Service men and ...
Breaking Medicine News(10 mins):Health News:ACLS Online Certification Website ACLS-PALS-BLS.com Now Features a New and User-Friendly Layout 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 3Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 4Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 5Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 3Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 3Health News:Discount Labels Donates Portion of November Sales to Hero Reward Program 2
... 2010 - The 1994 genocide in Rwanda resulted in the ... course of about 100 days. Although the exact death ... of the country,s entire population was murdered. There can ... survivors developed posttraumatic stress disorder, or PTSD, an anxiety disorder ...
... rats, treatment boosts blood vessel and nerve cell growth, researchers ... the results of preliminary research in rats, researchers say that ... could help people recover brain function after a stroke. , ... induced ischemic strokes showed signs of blood vessel growth and ...
... ... on Outsourcing , ... Westborough, MA (PRWEB) February 25, 2010 -- Advans, a solution provider and IT ... popularity of domestic outsourcing. According to the Advans’ IT Outsourcing Survey, 75 percent of ...
... ... Promises New Insight , ... Rosemont, IL (Vocus) February 25, 2010 -- Dr. Robert C. Bray of the ... Society for Sports Medicine’s (AOSSM) $250,000 Ligament and Tendon Repair and Regeneration Grant ...
... ... and overwhelmed state agencies are possible causes for the increase in health care inquiries. ... Cleveland, OH ... health insurance quotes from HealthInsuranceSort. The need for individual health insurance from private ...
... Researchers from the Toronto Western Research Institute noted a ... in the U.S. versus the Canadian population. The authors ... a greater level of obesity and physical inactivity in ... published in the March issue of Arthritis Care ...
Cached Medicine News:Health News:Rwandan genocide survivors provide new insights into resilience and PTSD 2Health News:Vitamin B3 May Help Repair Brain After a Stroke 2Health News:Advans Survey Reveals that 75 Percent of Executives Prefer Domestic Outsourcing vs. Offshore 2Health News:$250,000 Grant Awarded for Groundbreaking Ligament and Tendon Repair Research 2Health News:HealthInsuranceSort.com Provides Record Number of Health Insurance Quotes in 2009 2Health News:Obesity and physical inactivity poses arthritis risk, especially for women 2
For the qualitative detection of cardiac troponin I (cTnl) in human whole blood and serum specimens...
For the qualitative detection of cardiac troponin I (cTnl) in human whole blood and serum specimens...
For the qualitative detection of antibodies to Treponema pallidum in human serum, plasma and whole blood specimens...
For the qualitative detection of antibodies to HIV-1 and HIV-2 in human serum, plasma and whole blood specimens...
Medicine Products: